Cargando…
IL-6 modulation for COVID-19: the right patients at the right time?
The ongoing pandemic caused by the novel coronavirus SARS-CoV-2 has disrupted the global economy and strained healthcare systems to their limits. After the virus first emerged in late 2019, the first intervention that demonstrated significant reductions in mortality for severe COVID-19 in large-scal...
Autores principales: | Ascierto, Paolo Antonio, Fu, Binqing, Wei, Haiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042594/ https://www.ncbi.nlm.nih.gov/pubmed/33837054 http://dx.doi.org/10.1136/jitc-2020-002285 |
Ejemplares similares
-
Is IL-6 the Right Target in COVID-19 Severe Pneumonia?
por: Blot, Mathieu, et al.
Publicado: (2021) -
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
por: Bersanelli, Melissa, et al.
Publicado: (2021) -
IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013) -
Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020) -
Palliative cardiovascular care: The right patient at the right time
por: Sullivan, Mark F., et al.
Publicado: (2019)